Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 12;31(165):210220.
doi: 10.1183/16000617.0220-2021. Print 2022 Sep 30.

Recent advances in the management of pulmonary hypertension with interstitial lung disease

Aaron B Waxman  1 , Davide Elia  2 , Yochai Adir  3   4 , Marc Humbert  5 , Sergio Harari  2   6
Affiliations
Review

Recent advances in the management of pulmonary hypertension with interstitial lung disease

Aaron B Waxman et al. Eur Respir Rev. .

Abstract

Pulmonary hypertension (PH) is known to complicate various forms of interstitial lung disease (ILD), including idiopathic pulmonary fibrosis, the interstitial pneumonias and chronic hypersensitivity pneumonitis. Pathogenesis of PH-ILD remains incompletely understood, and probably has overlap with other forms of pre-capillary pulmonary hypertension. PH-ILD carries a poor prognosis, and is associated with increased oxygen requirements, and a decline in functional capacity and exercise tolerance. Despite most patients having mild-moderate pulmonary hypertension, more severe pulmonary hypertension and signs of right heart failure are observed in a subset of cases. Clinical suspicion and findings on pulmonary function, computed tomography and echocardiography are often the initial steps towards diagnosis. Definitive diagnosis is obtained by right heart catheterisation demonstrating pre-capillary pulmonary hypertension. Drugs approved for pulmonary arterial hypertension have been investigated in several randomised controlled trials in PH-ILD patients, leading to discouraging results until the recent INCREASE study. This review provides an overview of the current understanding, approach to diagnosis and recent advances in treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.B. Waxman reports grants from United Therapeutics, Gossamer and Altavant, and personal fees from ARIA-CV and Acceleron, outside the submitted work. Conflict of interest: D. Elia has nothing to disclose. Conflict of interest: Y. Adir reports personal fees from TEVA, SANOFI, Bayer and Pfizer, and grants and personal fees from GSK, AstraZeneca and Janssen, outside the submitted work; Conflict of interest: M. Humbert reports grants or contracts from Acceleron, Janssen and Merck to his institution; consulting fees from Acceleron, Janssen and Merck (Steering Committees for pulmonary hypertension); payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AOP, Janssen and Merck; and participation on Advisory Boards for Acceleron, Janssen, Merck and United Therapeutics. Conflict of interest: S. Harari reports personal fees from Roche, grants and personal fees from AstraZeneca and Boehringer Ingelheim, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
World Symposium on Pulmonary Hypertension classification of pulmonary hypertension. mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance.
FIGURE 2
FIGURE 2
Algorithm for diagnosis of pulmonary hypertension. SoB: shortness of breath; ECG: electrocardiogram; NT-proBNP: N-terminal pro-brain natriuretic peptide; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; KCO: transfer coefficient of the lung for carbon monoxide; 6MWT: 6-min walk test; CT: computed tomography; PA: pulmonary artery; CPET: cardiopulmonary exercise testing; V′/Q′: ventilation/perfusion ratio; PA–aO2: alveolar–arterial oxygen tension difference; VD: dead space volume; VT: tidal volume; PaETCO2: end-tidal arterial carbon dioxide tension; V′E: minute ventilation; V′CO2: carbon dioxide production; O2: oxygen; TRV: tricuspid regurgitant velocity; RA: right atrium; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; S′: systolic velocity.
See this image and copyright information in PMC

References

    1. Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med 2013; 34: 695–705. doi:10.1016/j.ccm.2013.08.004 - DOI - PubMed
    1. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl 2008; 160: 21–28. doi:10.1111/j.1742-1241.2008.01624.x - DOI - PubMed
    1. King CS, Shlobin OA. The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment. Chest 2020; 158: 1651–1664. doi:10.1016/j.chest.2020.04.046 - DOI - PubMed
    1. Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Curr Opin Pulm Med 2021; 27: 396–404. doi:10.1097/MCP.0000000000000790 - DOI - PubMed
    1. Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev 2013; 22: 292–301. doi:10.1183/09059180.00002713 - DOI - PMC - PubMed

MeSH terms